Últimas noticias sobre Jasper Therapeutics (NASDAQ:JSPR) Bolsa

JASPER THERAPEUTICS INC

Jasper Therapeutics

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Jasper Therapeutics, Inc. - Class A Common Stock

Jasper Therapeutics Inc

<a href="https://www.bloomberg.com/news/articles/2025-08-07/trump-to-sign-order-easing-path-for-private-assets-in-401-k-s" title="https://www.bloomberg.com/news/articles/2025-08-07/trump-to-sign-order-easing-path-for-private-assets-in-401-k-s">https://www.bloomberg.com/news/articles/2025-08-07/trump-to-sign-order-easing-path-for-private-assets-in-401-k-s</a>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

News

Retail Sales

Markets

Real Estate

COIN

Bloomberg: 'President Donald Trump will sign an executive order Thursday that aims to allow private equity, real estate, cryptocurrency and other alternative assets in 401(k)s'

RDNT

DeepHealth, A RadNet Subsidiary, Receives FDA 510(K) Clearance For TechLive Remote Scanning Solution; Vendor-Agnostic MR, CT, PET/CT And Ultrasound Platform Connects 300+ Systems And Reduces MRI Room Closures By 42%

First Advantage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FA#NASDAQ">FA</a>) affirms FY2025 Adj EPS guidance from $0.86-$1.03 to $0.86-$1.03 vs $0.94 analyst estimate. Affirms FY2025 sales outlook from $1.500 billion-$1.600 billion to $1.500 billion-$1.600 billion vs $1.528 billion estimate.

Guidance

First Advantage Affirms FY2025 Adj EPS Guidance of $0.86-$1.03 vs $0.94 Est; Affirms FY2025 Sales Guidance of $1.500B-$1.600B vs $1.528B Est

OSTX

OS Therapies Receives MHRA Scientific Advice, Submits ILAP Request For OST-HER2 In Prevention Of Recurrent Pulmonary Metastatic Osteosarcoma, Plans Project Orbis Collaboration And Secures October 2025 EMA Scientific Advice Meeting

Millicom Intl Cellular (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGO#NASDAQ">TIGO</a>) reported quarterly earnings of $0.90 per share which beat the analyst consensus estimate of $0.67 by 34.33 percent. This is a 100 percent increase over earnings of $0.45 per share from the same period last year.&nbsp;

Earnings

Earnings Beats

Earnings Misses

TIGO

Millicom Intl Cellular Q2 Adj. EPS $0.90 Beats $0.67 Estimate

WIIM

Rogers shares are trading higher following a report suggesting Starboard Value holds more than a 9% stake in the company and plans to make changes to boost shares.

SEACOR Marine Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMHI#NYSE">SMHI</a>) (the "Company" or "SEACOR Marine"), a leading provider of marine and support transportation services to offshore energy facilities worldwide, today announced that it has entered into definitive agreements for the sale of two 335 foot class liftboats to JAD Construction Limited for total gross proceeds of $76.0 million in cash and an estimated gain of $30.5 million. The net proceeds from the sales of these vessels are unencumbered and the transaction is expected to close during the third quarter of 2025, subject to customary closing conditions and regulatory approvals.

SMHI

SEACOR Marine Sells Two Liftboats for $76M, Expects $30.5M Gain in Q3 Windfall

FSLY

Fastly shares are trading higher after the company reported better-than-expected Q2 financial results and issued Q3 sales guidance above estimates. Also, the company announced the appointment of a new CFO.v

GRPN

Groupon shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance.

CRNC

Cerence shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY25 sales guidance above estimates.

BMBL

Bumble shares are trading lower after the company reported worse-than-expected Q2 EPS results.

MediaAlpha shares are trading higher after the company reported better-than-expected Q2 sales results and announced it reached a settlement with the FTC.

INTC

Intel shares are trading higher after President Trump said the US will put 100% tariffs on chips but said there would be no charge for companies committing to building in America.

Zai Lab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) affirms FY2025 sales outlook from $560.000 million-$590.000 million to $560.000 million-$590.000 million vs $567.559 million estimate.

ZLAB

Zai Lab Affirms FY2025 Sales Guidance of $560.000M-$590.000M vs $567.559M Est

Sprout Social shares are trading higher after the company reported better-than-expected Q2 financial results and issued Q3 sales guidance above estimates. Also, the company raised its FY25 sales guidance above estimates.

TNDM

Tandem Diabetes Care shares are trading lower after the company reported mixed Q2 financial results and narrowed its FY25 sales guidance below estimates.

ALNT

Allient shares are trading higher after the company reported better-than-expected Q2 financial results.

Montrose Environmental Group shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY25 sales guidance above estimates.

Information Services Group shares are trading higher after the company reported better-than-expected Q2 financial results.

GOLF

Acushnet Declared A Quarterly Cash Dividend Of $0.235 Per Share, Which Is Payable On September 19 To Shareholders Of Record On September 5

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Jasper Therapeutics, Inc. - JSPR

Legal

JSPR

ABVC BioPharma

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Aligos Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Century Therapeutics, Inc. - Common Stock

Century Therapeutics

Kala Bio

Kalaris Therapeutics, Inc. - Common Stock

Kalaris Therapeutics

Klotho Neurosciences, Inc. - Common Stock

Klotho Neurosciences

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

MAIA Biotechnology

Ovid Therapeutics

PepGen

Pluri

Prelude Therapeutics Incorporated - Common Stock

Prelude Therapeutics

Plus Therapeutics

Radiopharm Theranostics Limited - American Depositary Shares

Radiopharm Theranostics

RenovoRx

Senti Biosciences

Shattuck Labs

Exicure

Xilio Therapeutics

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative Preferred Stock

Comments

Jasper Therapeutics

Noticias

Últimas noticias sobre Jasper Therapeutics (NASDAQ:JSPR) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL